Could a common gout drug protect hearts when statins fail?
NCT ID NCT06874192
First seen Jun 24, 2026 · Last updated Jul 02, 2026 · Updated 3 times
Summary
This pilot study tests whether low-dose colchicine, an anti-inflammatory drug already approved for heart disease, is safe and can reduce inflammation in 30 adults who cannot take statins due to side effects. Participants will take either colchicine or a placebo daily for four weeks. The goal is to see if colchicine can lower inflammatory markers like hs-CRP, potentially offering a new way to reduce heart risk in this group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- low-dose colchicine (0.5 mg daily)
- What this could lead to
- If it works, this could offer a way to lower heart disease risk in people who can't take statins.
- What could go wrong
- This is a very early, small pilot study with only 30 people over 4 weeks. It may not show clear benefits or safety issues may arise.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STATIN ADVERSE REACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.